Opdivo was first approved in July of 2014 in Japan for the treatment of unresectable melanoma and later in December the same year in the US or the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor (Press release Bristol-Myers Squibb, DEC 22, 2014, View Source [SID:1234501237]).

On January 27, 2015 Bristol-Myers Squibb reported accrued sales in US dollars for Opdivo during 2014 (Filing Q4/Annual , Bristol-Myers Squibb, JAN 27, 2015, View Source [SID:1234501395]):
USA: $1M
Non-US (Japan): $5M
Worldwide: $6M